0B68 Brody, Jonathan R - Thomas Jefferson University - Thomas Jefferson University
jrb006

Jonathan R. Brody, PhD

Contact Dr. Brody

1015 Walnut Street
Curtis Building, Suite 611A
Philadelphia, PA 19107

(215) 955-2693

Most Recent Peer-reviewed Publications

  1. HuR posttranscriptionally regulates WEE1: Implications for the DNA damage response in pancreatic cancer cells
  2. Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer
  3. Structural implications for selective targeting of PARPs
  4. Targeting cell cycle and hormone receptor pathways in cancer
  5. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival
  6. HuR is a post-transcriptional regulator of core metabolic enzymes in pancreatic cancer
  7. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer
  8. Pancreatic cancer and premalignant tumors: Molecular aspects
  9. Molecular-based and alternative therapies for pancreatic cancer: Looking "out of the box"
  10. HuR's post-transcriptional regulation of death receptor 5 in pancreatic cancer cells
  11. Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma
  12. A novel survival-based tissue microarray of pancreatic cancer validates muc1 and mesothelin as biomarkers
  13. Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient
  14. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organized
  15. Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
  16. Loss of stromal Caveolin-1 expression in malignant melanoma metastases predicts poor survival
  17. Subject Review: Pancreatic Ductal Adenocarcinoma in the Setting of Mutations in the Cystic Fibrosis Transmembrane Conductance Regulator Gene: Case Report and Review of the Literature
  18. The Past, Present, and Future of Biomarkers: A Need for Molecular Beacons for the Clinical Management of Pancreatic Cancer
  19. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers
  20. HuR's role in gemcitabine efficacy: An exception or opportunity?
0